France’s national health system is set to begin reimbursing two of the most promising obesity treatments—Wegovy and Mounjaro—starting June 15, 2026. But a controversial policy decision by the Assurance Maladie, the French public health insurer, is already sparking backlash from medical groups who warn it will make these life-changing therapies nearly inaccessible to the patients who need them most.
In a move that health advocates call “a step backward in patient care,” the insurer has excluded general practitioners from prescribing the drugs, restricting access to a narrow group of specialists. The decision, which takes effect this month, comes as obesity rates continue to rise across Europe, with an estimated 17% of French adults now classified as severely obese—a condition linked to higher risks of diabetes, heart disease, and early mortality.
Why the Controversial Prescription Rules?
The policy stems from a cost-control strategy. Wegovy, a GLP-1 receptor agonist developed by Novo Nordisk, and Mounjaro, a dual GLP-1/GIP agonist from Eli Lilly, have shown remarkable efficacy in clinical trials—with some patients losing up to 15% of their body weight over a year. But their high price tags (around $1,300 per month before reimbursement) have made them financial liabilities for insurers. By limiting prescriptions to specialists rather than general practitioners, the Assurance Maladie estimates it can reduce the number of claims by as much as 40%, slashing an estimated €100 million in annual costs.
“This isn’t about patient access—it’s about shifting the burden onto patients who already face barriers to care,” said a spokesperson for MG France, the national association of general practitioners. “Generalists are the first line of defense for obesity treatment, yet we’re being systematically excluded from the process. The real question is: Why isn’t the government negotiating lower drug prices instead of making it harder for people to get the help they need?”
Who Will Actually Get Access?
Under the new rules, only endocrinologists, diabetologists, and a few other specialists will be authorized to prescribe Wegovy and Mounjaro. Patients will still need a referral from their general practitioner to see a specialist—a step that, in a country with chronic doctor shortages, could create additional delays. Meanwhile, the insurer has also narrowed the approved indications for reimbursement, aligning them more closely with the drugs’ original marketing authorizations, which may exclude some patients who could still benefit.
Nutritionists and public health experts warn the policy could deepen health disparities. “Obesity is a complex, multifactorial disease, and patients in rural areas or underserved communities already struggle to see specialists,” said one Colmar-based nutritionist, who called the decision “a missed opportunity to modernize obesity care.” “These drugs aren’t just about weight loss—they’re about reducing the risk of diabetes, stroke, and other comorbidities. Cutting off access to the doctors who know these patients best is reckless.”
What’s Next for Obesity Treatment in France?
The controversy has reignited debates about drug pricing and healthcare equity in France. While the Assurance Maladie insists the move is necessary to control spending, critics argue it ignores the broader economic costs of untreated obesity—including higher long-term healthcare expenses for conditions like type 2 diabetes and cardiovascular disease. Some lawmakers have already signaled they may push for legislative changes to reverse the prescription restrictions.
In the meantime, patients facing obesity will have to navigate a fragmented system where access hinges on geography, specialist availability, and bureaucratic hurdles. For now, the only certainty is that the fight over who gets to prescribe these groundbreaking treatments—and who pays for them—is far from over.
